申联生物医药（上海）股份有限公司兰州分公司获批猪链球菌病、传染性胸膜肺炎二联灭活疫苗（2型 ZY - 2株+1型SC株）兽药产品批准文号（兽药生字280181168），有效期至2030年。该疫苗用于预防猪 两种常见传染病，以"精准菌株"等实现"一苗防两病、高效低应激"，对防控意义重大。产品具备上市销 售条件，上市前仅需履行批签发程序。获批将完善公司兽用细菌病防控产品矩阵，提升产能利用率。 ...

Market Overview - The animal health sector increased by 1.25% on September 5, with Yongshun Biological leading the gains [1] - The Shanghai Composite Index closed at 3812.51, up 1.24%, while the Shenzhen Component Index closed at 12590.56, up 3.89% [1] Stock Performance - Yongshun Biological (839729) closed at 10.82, up 4.14% with a trading volume of 44,500 shares and a turnover of 47.80 million yuan [1] - Shilian Biological (688098) closed at 11.76, up 3.16% with a trading volume of 114,100 shares and a turnover of 132 million yuan [1] - Other notable performers include: - Houfeng Holdings (002141): closed at 3.96, up 2.33% [1] - KQ Biological (688526): closed at 18.00, up 2.16% [1] - Dayu Biological (871970): closed at 10.25, up 2.09% [1] Capital Flow - The animal health sector experienced a net outflow of 37.19 million yuan from institutional investors, while retail investors saw a net inflow of 13.24 million yuan [2] - Notable capital flows include: - Shilian Biological: net inflow of 500.11 thousand yuan from institutional investors [3] - Houfeng Holdings: net inflow of 91.15 thousand yuan from retail investors [3] - KQ Biological: net outflow of 297.54 thousand yuan from institutional investors [3]

Market Overview - The animal health sector experienced a decline of 0.2% on September 4, with Shunlian Biological leading the drop [1] - The Shanghai Composite Index closed at 3765.88, down 1.25%, while the Shenzhen Component Index closed at 12118.7, down 2.83% [1] Stock Performance - Notable gainers in the animal health sector included: - Qudongli (code: 838275) with a closing price of 11.96, up 6.50% [1] - Dayu Biological (code: 871970) with a closing price of 10.04, up 3.40% [1] - Yongshun Biological (code: 839729) with a closing price of 10.39, up 2.26% [1] - Conversely, Shunlian Biological (code: 688098) saw a decline of 2.98%, closing at 11.40 [2] Trading Volume and Capital Flow - The total trading volume for the animal health sector showed a net outflow of 85.41 million yuan from institutional investors, while retail investors saw a net inflow of 74.17 million yuan [2] - The capital flow for individual stocks indicated significant movements, with Shunlian Biological experiencing a net outflow of 10.12 million yuan from institutional investors [3] Individual Stock Analysis - Shunlian Biological had a total trading volume of 131,200 shares, with a net inflow of 7.73 million yuan from retail investors [3] - Other stocks like Huisheng Biological (code: 300871) and ST Green Kang (code: 002868) also showed varied capital flows, with Huisheng experiencing a net outflow of 12.50 million yuan from speculative funds [3]

集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 会议召开时间：2025 年 9 月 16 日（星期二）15:00-17:00 证券代码：688098 证券简称：申联生物 公告编号：2025-034 申联生物医药（上海）股份有限公司 关于参加 2025 年半年度科创板创新药行业 ? 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow. sseinfo.com/） ? 会议召开方式：上证路演中心网络文字互动 ? 投资者可于 2025 年 9 月 9 日（星期二）至 9 月 15 日（星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 slsw@sl bio.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 申联生物医药（上海）股份有限公司（以下简称"公司"）已于 2025 年 8 月 30 日发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 年度科创板创新药行业集体业绩说明会，就投资 ...

Market Overview - The animal health sector experienced a decline of 2.2% on September 3, with the leading stock, Driveline, falling by 8.33% [1] - The Shanghai Composite Index closed at 3813.56, down 1.16%, while the Shenzhen Component Index closed at 12472.0, down 0.65% [1] Stock Performance - Key stocks in the animal health sector showed significant declines, with Driveline (code: 838275) closing at 11.23, down 8.33% on a trading volume of 49,500 shares and a transaction value of 57.66 million yuan [1] - Other notable declines included: - Yongshun Biological (code: 839729) down 4.78% to 10.16 [1] - Jinhai Biological (code: 002688) down 4.03% to 6.91 [1] - ST Lvkang (code: 002868) down 3.30% to 26.35 [1] - Houbang Holdings (code: 002141) down 3.24% to 3.88 [1] Capital Flow - The animal health sector saw a net outflow of 108 million yuan from major funds, while retail investors contributed a net inflow of 101 million yuan [1] - Detailed capital flow for specific stocks indicated: - Shunlian Biological (code: 688098) had a net inflow of 8.21 million yuan from major funds [2] - ST Lvkang (code: 002868) experienced a net outflow of 2.26 million yuan from major funds [2] - Houbang Holdings (code: 002141) faced a significant net outflow of 24.59 million yuan from major funds [2]

重要内容提示： 会议召开时间：2025 年 9 月 16 日（星期二）15:00-17:00 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow. sseinfo.com/） 会议召开方式：上证路演中心网络文字互动 投资者可于 2025 年 9 月 9 日（星期二）至 9 月 15 日（星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 slsw@sl bio.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 申联生物医药（上海）股份有限公司（以下简称"公司"）已于 2025 年 8 月 30 日发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况及战略布局创新药进展等情况，公司计划于 2 025 年 9 月 16 日（星期二）15:00-17:00 参加由上海证券交易所举办的 2025 年半 年度科创板创新药行业集体业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 证券代码：688098 证券简称：申联生物 公告编号：2025-034 申联生物医药（上海）股份 ...

Core Viewpoint - The animal health sector experienced a decline of 2.73% on September 2, with Shunlian Biological leading the drop [1][2]. Market Performance - The Shanghai Composite Index closed at 3858.13, down 0.45% - The Shenzhen Component Index closed at 12553.84, down 2.14% [1]. Individual Stock Performance - Notable gainers included: - Qudongli (code: 838275) with a closing price of 12.25, up 3.38% on a trading volume of 52,700 shares and a turnover of 63.41 million yuan - Yongshun Biological (code: 839729) with a closing price of 10.67, up 1.62% on a trading volume of 36,800 shares and a turnover of 38.93 million yuan - Significant decliners included: - Shunlian Biological (code: 688098) with a closing price of 11.79, down 6.43% on a trading volume of 169,400 shares and a turnover of 203 million yuan - Jinhe Biological (code: 002688) with a closing price of 7.20, down 4.38% on a trading volume of 527,700 shares and a turnover of 382 million yuan [1][2]. Capital Flow Analysis - The animal health sector saw a net outflow of 259 million yuan from institutional investors, while retail investors contributed a net inflow of 199 million yuan [2][3]. - Key stocks with significant capital flow include: - Qianhe Biological (code: 002688) with a net outflow of 67.31 million yuan from institutional investors - Shunlian Biological (code: 688098) with a net outflow of 26.38 million yuan from institutional investors [3].

Group 1 - Weisheng Information won four projects in August with a total amount of 85.5377 million yuan, accounting for 3.12% of the company's total revenue for 2024 [1] - Longqi Technology's shareholder plans to reduce its stake by up to 4.09%, equating to a maximum of 19.1916 million shares [1] - Guojin Modern's subsidiary received a drug registration certificate for injectable Nicardipine, used for treating unstable angina [3][4] Group 2 - SAIC Motor reported a total vehicle sales of 363,400 units in August, a year-on-year increase of 41.04%, with new energy vehicle sales reaching 129,800 units, up 49.89% [5] - Kuka Home plans to invest 1.124 billion yuan to build a self-owned base in Indonesia, aiming to enhance its international strategy [6] - Samsung Medical's subsidiary signed a contract for an intelligent meter project in Egypt worth 58.8 million USD, approximately 419 million yuan [8] Group 3 - North Vehicle Blue Valley's subsidiary reported a total production of 10,587 units in August, a year-on-year decrease of 15.13%, while sales increased by 3.47% [12] - Xianghe Industrial signed contracts worth 400 million yuan for railway fastener system components [13] - Hengrui Medicine's HRS9531 injection has received acceptance for its marketing authorization application [14] Group 4 - Hualu Hengsheng resumed normal production after completing maintenance on production facilities [16] - Shanghai Pharmaceuticals' hydrochloride verapamil injection passed the consistency evaluation for generic drugs [18] - Shanghai Construction received approval for debt financing tools with a registration period of two years [20] Group 5 - Kangli Elevator terminated the sale of its wholly-owned subsidiary due to the buyer's failure to obtain necessary approvals [21] - Times Wan Heng appointed Li Zhizhong as the new deputy general manager [22] - Hanma Technology reported a total truck sales of 1,051 units in August, a year-on-year increase of 58.05% [24] Group 6 - Wenzhou Hongfeng's subsidiary received a utility model patent certificate for a servo adjustment device [26] - Yibin Technology received a project designation from a domestic new energy vehicle company, with an estimated total sales of 243 million yuan over five years [28] - Star Ring Technology's H-share issuance application was accepted by the China Securities Regulatory Commission [30] Group 7 - Microchip Bio's vice president resigned for personal reasons [31] - Zhongxin Co. announced the resignation of a non-independent director due to personal reasons [32] - Changcheng Military Industry's vice chairman resigned due to retirement [35] Group 8 - Jiukang Bio received four invention patent certificates related to detection reagents [36] - Meino Bio's subsidiary changed its registered address [37] - Kuangda Technology announced a potential change in control due to a share transfer [38] Group 9 - China Rare Earth confirmed no undisclosed significant matters amid stock price fluctuations [72]

Market Overview - The animal health sector increased by 1.34% on September 1, with Jinhe Biology leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Stock Performance - Jinhe Biology (002688) closed at 7.53, up 6.06% with a trading volume of 875,700 shares and a turnover of 651 million yuan [1] - Other notable performers included *ST Lvkang (002868) with a 5.02% increase, and Shunlian Biology (688098) with a 1.78% increase [1] - The overall trading data for the animal health sector is summarized in the provided table [1] Capital Flow - The animal health sector saw a net inflow of 26.58 million yuan from institutional investors, while retail investors experienced a net outflow of 7.06 million yuan [2] - The detailed capital flow for individual stocks indicates varying levels of institutional and retail participation [3] Individual Stock Analysis - Jinhe Biology had a net inflow of 88.59 million yuan from institutional investors, while retail investors showed a net outflow of 37.91 million yuan [3] - Other stocks like Kexin Biology (688526) and *ST Lvkang (002868) also experienced mixed capital flows, with significant retail outflows [3]

Group 1 - The company has received an update on the progress of the innovative drug UB-221's Phase II clinical research from its associate company, Yangzhou Shizhi Source Biotechnology Co., Ltd. [1] - UB-221 is a humanized monoclonal antibody developed by the inventor of the anti-IgE therapy, Dr. Zhang Ziwen, and is designed to treat allergic reactions by neutralizing free IgE and inhibiting its synthesis [2][1]. - The ongoing Phase II clinical trial is a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of UB-221 in patients with chronic spontaneous urticaria (CSU), with a target enrollment of 144 patients, ultimately recruiting 145 [2]. Group 2 - The company is focused on building a world-class high-tech biopharmaceutical company and is actively expanding its business into the human innovative drug sector, leveraging its diverse biopharmaceutical technology platforms and talent reserves [3]. - The company is advancing the development of three innovative drugs: UB-221, UB-421, and UB-621, while also exploring new indications, supported by its technological expertise in synthetic peptides, genetic engineering, and mRNA [3].